← Back to Search

GLP-1 Receptor Agonist

Semaglutide for Obesity

Phase 4
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. The parent(s) or legally acceptable representative (LAR) of the participant must sign and date the Informed Consent Form, according to local requirements
2. The participant must sign and date the Child Assent Form or provide oral assent, according to local requirements
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
Awards & highlights

Summary

The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.

Who is the study for?
This trial is for teenagers with excess body weight who are interested in losing and maintaining weight loss. Participants will receive weekly injections of semaglutide for at least 3 years. Specific eligibility criteria details were not provided.
What is being tested?
The study focuses on the effectiveness of semaglutide, administered through weekly injections, in helping overweight adolescents lose and maintain their weight over a minimum period of three years.
What are the potential side effects?
Potential side effects from semaglutide may include digestive issues like nausea or diarrhea, possible injection site reactions, and changes in appetite. More specific side effect information was not provided.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 1.5 years to 3 years and end of continued treatment phase (up to 6 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 1.5 years to 3 years and end of continued treatment phase (up to 6 years) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maintenance of Body Mass Index (BMI) below obesity threshold
Secondary study objectives
Achieving Body Mass Index (BMI) below obesity threshold
Achieving any improvement in Body Mass Index (BMI) category
Body Mass Index (BMI) percentage of the 95th percentile
+17 more

Side effects data

From 2020 Phase 4 trial • 104 Patients • NCT04189848
21%
Nausea
12%
Decreased Appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Overall Study

Trial Design

1Treatment groups
Experimental Treatment
Group I: SemaglutideExperimental Treatment1 Intervention
2.4mg or maximum tolerated dose(MTD) injected subcutaneously (under the skin, s.c) once weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
2021
Completed Phase 4
~5160

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,534 Previous Clinical Trials
2,422,358 Total Patients Enrolled
149 Trials studying Obesity
132,752 Patients Enrolled for Obesity
Clinical Transparency (dept. 2834)Study DirectorNovo Nordisk A/S
119 Previous Clinical Trials
143,167 Total Patients Enrolled
35 Trials studying Obesity
50,122 Patients Enrolled for Obesity
~333 spots leftby Nov 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top